Back to top
more

Gilead Sciences (GILD)

(Real Time Quote from BATS)

$74.38 USD

74.38
785,910

+0.60 (0.81%)

Updated Aug 19, 2024 11:20 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (70 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Outlook: Approval of New Drugs to Boost Performance

by Zacks Equity Research

While decline in sales of high-profile drugs and competitive pressure are likely to weigh on the biotech sector, we expect approval of new drugs to offset the impact of the same.

Bristol-Myers' Opdivo Receives Positive CHMP Opinion for RCC

by Zacks Equity Research

Bristol-Myers' (BMY) immuno-oncology drug Opdivo combined with low-dose Yervoy gets positive opinion from CHMP for the treatment of intermediate- and poor-risk advanced RCC.

Sangamo's Shares Drop on Rating Downgrade, Pipeline Woes

by Zacks Equity Research

Sangamo Therapeutics (SGMO) postpones data presentation from its haemophilia study, following dose escalation recommendation from an independent committee. This raises concerns about its development.

Acorda Down More Than 30% in the Past 3 Months: Here's Why

by Zacks Equity Research

Acorda's (ACOR) lead MS drug Ampyra is hit by generic competition in the United States while its lead Parkinson disease candidate Inbrija's review timeline gets extended by three months.

BeiGene (BGNE) Catches Eye: Stock Jumps 8.3%

by Zacks Equity Research

BeiGene (BGNE) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Biotech Stock Roundup: Gilead, Regeneron Present Data, Cocrystal Pharma Surges

by Zacks Equity Research

With the earnings season coming to an end, data presentations on key drugs and candidates hog the limelight this week.

Roche's Tecentriq Gets Priority Review for Breast Cancer

by Zacks Equity Research

Roche's efforts to expand the label of its immuno-oncology drug Tecentriq advances as the FDA accepts its sBLA and grants priority review for the treatment of breast cancer.

Amarin's Vascepa Cuts Heart Risk in Outcomes Test, Stock Down

by Zacks Equity Research

Amarin (AMRN) posts detailed data from a late-stage cardiovascular outcomes study on its fish oil drug Vascepa. The stock takes a hit.

Cronos (CRON) to Report Q3 Earnings: What's in the Offing?

by Zacks Equity Research

Cronos' (CRON) third-quarter results are likely benefit from the company's collaboration initiatives to become one of the most promising cannabis company.

Tilray (TLRY) to Report Q3 Earnings: What's in the Cards?

by Zacks Equity Research

We expect investors to focus on Tilray's (TLRY) pipeline updates when it reports third-quarter results.

    Medicines Company (MDCO) Q3 Loss Widens, Inclisiran in Focus

    by Zacks Equity Research

    The Medicines Company (MDCO) suffers a wider-than-expected loss in Q3. At the same time, the company posts negative revenues.

    Endo (ENDP) Stock Declines Despite Q3 Earnings & Revenue Beat

    by Zacks Equity Research

    Endo (ENDP) tops revenues and earnings expectations in the third quarter and raises its annual view. However, the results from the cellulite treatment trial are disappointing.

      Arena Pharmaceuticals (ARNA) Beats on Q3 Earnings and Sales

      by Zacks Equity Research

      Arena Pharmaceuticals (ARNA) betters loss estimates in Q3. Also, the top line surpasses the consensus mark.

      Aerie (AERI) Q3 Earnings Miss, Rhopressa Gains Traction

      by Zacks Equity Research

      Aerie's (AERI) Q3 loss is wider than expected on account of higher expenses. Nevertheless, Rhopressa's sales beat estimates as demand picks up.

      PDL BioPharma (PDLI) Q3 Earnings Top, Revenues Rise, Stock Up

      by Zacks Equity Research

      PDL BioPharma's (PDLI) earnings trump estimates in Q3. Higher royalties and product sales aid a significant surge in year-over-year revenues.

      Prothena (PRTA) Reports Narrower-Than-Expected Loss in Q3

      by Zacks Equity Research

      Prothena (PRTA) posts narrower-than-expected loss in the third quarter. With the failure of lead drug, NEOD001, the focus is now on its mid-stage candidate, prasinezumab.

      Pacira (PCRX) Q3 Earnings and Revenues Surpass Estimates

      by Zacks Equity Research

      Pacira Pharmaceuticals (PCRX) encourages with better-than-expected earnings and revenues in Q3

      Puma Biotech (PBYI) Q3 Loss Narrows, Nerlynx Pulls Stock Down

      by Zacks Equity Research

      Puma Biotech (PBYI) betters loss estimates in Q3. However, its only marketed drug, Nerlynx, disappoints with low sequential growth and as a result, shares take a hit.

      Radius Health (RDUS) Posts Narrower-Than-Expected Q3 Loss

      by Zacks Equity Research

      Radius Health (RDUS) posts narrower Q3 loss as Tymlos sales gains traction.

      Agios (AGIO) Q3 Earnings Beat, Tibsovo Sales Drive Stock

      by Zacks Equity Research

      Agios' (AGIO) loss tops estimates in Q3. Its precision medicine Tibsovo's performance in the very first quarter after approval in July leads to a significant year-over-year revenue growth.

      Emergent (EBS) Q3 Earnings and Revenues Fall Shy of Estimates

      by Zacks Equity Research

      Emergent (EBS) disappoints with weaker-than-expected results in the third quarter of 2018.

      Conatus' (CNAT) Q3 Loss In Line, Revenues Lag Estimates

      by Zacks Equity Research

      Conatus (CNAT) incurs in-line loss for the third quarter of 2018. Sales miss estimates.

      bluebird (BLUE) Q3 Loss Narrower Than Expected, Revenues Beat

      by Zacks Equity Research

      bluebird (BLUE) incurs narrower-than-expected Q3 loss on account of higher collaboration revenues. The pipeline progress looks encouraging.

      Biotech ETFs in Focus on String of Q3 Earnings Beat

      by Zacks Equity Research

      Biotech ETFs draw attention post impressive Q3 results.

      Acorda (ACOR) Q3 Earnings Top Estimates, Ampyra Sales View Up

      by Zacks Equity Research

      Acorda's (ACOR) Q3 rides high on earnings and revenue beat amid a strong generic competition for its MS drug Ampyra and the expected launch of its Parkinson's candidate, Inbrija.